Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pedro Cahn

Showing results (141-150 of 207) with videos related to

Pageof 21
Sort By:
Journal of the International AIDS Society|April 12, 2016
Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppressionPeter F Rebeiro, Carina Cesar, Bryan E Shepherd, et al.
The Lancet. HIV|November 2, 2015
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort studyCarina Cesar, Cathy A Jenkins, Bryan E Shepherd, et al.
Plos One|June 27, 2017
A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapyMarcelo J Wolff, Mark J Giganti, Claudia P Cortes, et al.
Journal of the International AIDS Society|March 24, 2018
Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean CohortGabriela Carriquiry, Mark J Giganti, Jessica L Castilho, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 12, 2009
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the CaribbeanSuely H Tuboi, Mauro Schechter, Catherine C McGowan, et al.
The Lancet. HIV|November 20, 2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
Infectious Agents and Cancer|May 16, 2018
Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin AmericaValeria I Fink, Cathy A Jenkins, Jessica L Castilho, et al.
Open Forum Infectious Diseases|July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled AnalysisStefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Plos Medicine|April 25, 2012
Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classificationLivio Azzoni, Andrea S Foulkes, Yan Liu, et al.
JAMA|July 14, 2004
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trialMichael S Saag, Pedro Cahn, François Raffi, et al.
Pageof 21

Showing results (141-150 of 207) with videos related to

Sort By:
Pageof 21
Journal of the International AIDS Society|April 12, 2016
Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppressionPeter F Rebeiro, Carina Cesar, Bryan E Shepherd, et al.
The Lancet. HIV|November 2, 2015
Incidence of virological failure and major regimen change of initial combination antiretroviral therapy in the Latin America and the Caribbean: an observational cohort studyCarina Cesar, Cathy A Jenkins, Bryan E Shepherd, et al.
Plos One|June 27, 2017
A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapyMarcelo J Wolff, Mark J Giganti, Claudia P Cortes, et al.
Journal of the International AIDS Society|March 24, 2018
Virologic failure and mortality in older ART initiators in a multisite Latin American and Caribbean CohortGabriela Carriquiry, Mark J Giganti, Jessica L Castilho, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|May 12, 2009
Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the CaribbeanSuely H Tuboi, Mauro Schechter, Catherine C McGowan, et al.
The Lancet. HIV|November 20, 2019
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trialJean-Michel Molina, Kathleen Squires, Paul E Sax, et al.
Infectious Agents and Cancer|May 16, 2018
Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin AmericaValeria I Fink, Cathy A Jenkins, Jessica L Castilho, et al.
Open Forum Infectious Diseases|July 17, 2024
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled AnalysisStefan Scholten, Pedro Cahn, Joaquín Portilla, et al.
Plos Medicine|April 25, 2012
Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classificationLivio Azzoni, Andrea S Foulkes, Yan Liu, et al.
JAMA|July 14, 2004
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trialMichael S Saag, Pedro Cahn, François Raffi, et al.
Pageof 21